AngioDynamics (ANGO) Stock Price, News & Analysis

Company Overview

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.

Key Stats

• Today's Range: $9.33 to $9.67
• 50-Day Range: $8.63 to $11.14
• 52-Week Range: $5.47 to $13.50
• Volume: 508,291 shs
• Average Volume: 583,350 shs
• Market Capitalization: $381.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

AngioDynamics Stock Analysis - MarketRank™

AngioDynamics scored higher than 80% of companies evaluated by MarketBeat, and ranked 235th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

AngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

AngioDynamics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AngioDynamics are expected to grow in the coming year, from ($0.37) to ($0.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AngioDynamics is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AngioDynamics is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AngioDynamics has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.61% of the float of AngioDynamics has been sold short.

Short Interest Ratio / Days to Cover

AngioDynamics has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in AngioDynamics has recently increased by 31.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AngioDynamics does not currently pay a dividend.

Dividend Growth

AngioDynamics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.99

Percentage of Shares Shorted

6.61% of the float of AngioDynamics has been sold short.

Short Interest Ratio / Days to Cover

AngioDynamics has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in AngioDynamics has recently increased by 31.61%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

AngioDynamics has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for AngioDynamics this week, compared to 3 articles on an average week.

Search Interest

Only 4 people have searched for ANGO on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AngioDynamics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.40% of the stock of AngioDynamics is held by insiders.

Percentage Held by Institutions

89.43% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ANGO Stock Analysis - Frequently Asked Questions

How have ANGO shares performed this year?

AngioDynamics' stock was trading at $9.16 on January 1st, 2025. Since then, ANGO stock has increased by 2.5% and is now trading at $9.39.
View the best growth stocks for 2025 here.

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings data on Wednesday, April, 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.13) by $0.16. The business's revenue was down 4.3% compared to the same quarter last year.
Read the conference call transcript.

Does AngioDynamics have any subsidiaries?

AngioDynamics subsidiaries include these companies: Eximo Medical Ltd., RadiaDyne LLC, Clinical Devices, Vortex Medical, Navilyst Medical Inc., FlowMedica, Oncovionic, and more.

How do I buy shares of AngioDynamics?

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AngioDynamics investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), Voyager Therapeutics (VYGR), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 4/02/2025
• Today: 7/02/2025
• Next Earnings (Estimated): 7/15/2025
• Fiscal Year End: 5/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:ANGO
• CIK: 1275187
• Web: www.angiodynamics.com
• Phone: (518) 795-1400
• Fax: 518-795-1401
• Employees: 760
• Year Founded: 1988

Price Target and Rating

• Average Stock Price Target: $14.00
• High Stock Price Target: $16.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +49.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$184.35 million
• Net Margins: -14.61%
• Pretax Margin: -14.85%
• Return on Equity: -3.73%
• Return on Assets: -2.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.21
• Quick Ratio: 1.40

Sales & Book Value

• Annual Sales: $303.91 million
• Price / Sales: 1.25
• Cash Flow: $4.06 per share
• Price / Cash Flow: 2.31
• Book Value: $5.13 per share
• Price / Book: 1.83

Miscellaneous

• Outstanding Shares: 40,610,000
• Free Float: 38,414,000
• Market Cap: $380.72 million
• Optionable: Optionable
• Beta: 0.60